Literature DB >> 8700533

HER-2/c-erbB2 is phosphorylated by calmodulin-dependent protein kinase II on a single site in the cytoplasmic tail at threonine-1172.

R L Feinmesser1, K Gray, A R Means, A Chantry.   

Abstract

Calmodulin-dependent protein kinase II (Cam kinase II) is known to desensitise epidermal growth factor receptor (HER-1) tyrosine kinase activity by a process involving phosphorylation at serines 1046/47 in the cytoplasmic tail. We have developed an experimental system to investigate phosphorylation of the related HER-2/c-erbB2 proto-oncogene utilising purified Cam kinase II and recombinant glutathione-S-transferase (GST) fusion proteins. The cDNA for rat Cam kinase II-alpha was transfected into human embryonic kidney (HEK) 293 fibroblasts and the expressed protein purified to homogeneity by calmodulin-agarose affinity chromatography. A GST fusion protein comprising residues 1126-1255 of HER-2 was phosphorylated by purified Cam kinase II, in contrast to a GST protein comprising residues 1005-1125. Phosphoamino-acid analysis and site-directed mutagenesis indicated that HER-2 was phosphorylated on a single site at threonine-1172 which resides within a consensus Cam kinase II phosphorylation site (RAKT). HER-2 (threonine-1172-alanine), in the form of a ligand-inducible chimaera HER-1/2, was co-transfected into HEK-293 fibroblasts with a constitutively active form of Cam kinase II, followed by in vivo labelling of these cells with 32 P-orthophosphate. Immunoprecipitation of ligand-activated receptors followed by two-dimensional phosphopeptide mapping indicated that threonine-1172 in HER-2 is a newly identified in vivo site which can be hyper-phosphorylated by constitutively active Cam kinase II. In addition, when over-expressed in HEK-293 fibroblasts, HER-1/2 (threonine-1172-alanine) showed a defect in desensitisation and underwent a more sustained EGF-induced receptor autophosphorylation compared to wild-type HER-1/2.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8700533

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Inactivation of smad-transforming growth factor beta signaling by Ca(2+)-calmodulin-dependent protein kinase II.

Authors:  S J Wicks; S Lui; N Abdel-Wahab; R M Mason; A Chantry
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

2.  Association of ErbB2 Ser1113 phosphorylation with epidermal growth factor receptor co-expression and poor prognosis in human breast cancer.

Authors:  X Ouyang; T Gulliford; H Zhang; G Smith; G Huang; R J Epstein
Journal:  Mol Cell Biochem       Date:  2001-02       Impact factor: 3.396

3.  The ErbB2/Neu/HER2 receptor is a new calmodulin-binding protein.

Authors:  Hongbing Li; Juan Sánchez-Torres; Alan Del Carpio; Valentina Salas; Antonio Villalobo
Journal:  Biochem J       Date:  2004-07-01       Impact factor: 3.857

4.  Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways.

Authors:  Koshi Imami; Naoyuki Sugiyama; Haruna Imamura; Masaki Wakabayashi; Masaru Tomita; Masatoshi Taniguchi; Takayuki Ueno; Masakazu Toi; Yasushi Ishihama
Journal:  Mol Cell Proteomics       Date:  2012-09-10       Impact factor: 5.911

Review 5.  Mechanistic aspects of crosstalk between GH and PRL and ErbB receptor family signaling.

Authors:  Stuart J Frank
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-31       Impact factor: 2.673

6.  AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer.

Authors:  Teraneh Z Jhaveri; Juhyung Woo; Xiaobin Shang; Ben Ho Park; Edward Gabrielson
Journal:  Oncotarget       Date:  2015-06-20

7.  The multidrug resistance 1 gene Abcb1 in brain and placenta: comparative analysis in human and guinea pig.

Authors:  Jane J Pappas; Sophie Petropoulos; Matthew Suderman; Majid Iqbal; Vasilis Moisiadis; Gustavo Turecki; Stephen G Matthews; Moshe Szyf
Journal:  PLoS One       Date:  2014-10-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.